Article

barrons.com on 2019-08-14 15:05

Myriad Genetics Craters on Weak Earnings, FDA Scrutiny

Shares of the molecular-diagnostic biotech firm were down 30.4% after the company reported financial results that missed expectations and it said the ...

Related news